SSY Group (HK:2005) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SSY Group Limited has announced that their Nefopam Hydrochloride Injection, a treatment for acute pain such as postoperative discomfort, has become the first generic drug to pass the Consistency Evaluation of Quality and Efficacy by China’s National Medical Products Administration. This milestone is part of the company’s recent product development updates intended to inform shareholders and potential investors about the company’s progress.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
